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Letters to the Editor
been in someof thesepatients the treatmentof choice. In fact, it has
to be considered as the gold standard. Additionally, according to a
recently published, well conducted systemic review 5-year sur-
vival rate (including perioperative mortality of up to 5%) after
resection for HCC fulﬁlling MC was 67% (27–81%) [5].
Otto et al. [1] report a similar overall 5-year survival rate of
70% following transplantation, but it remains unclear why resec-
tion was not attempted at least in selected patients in the pre-
sented series.
Furthermore, liver transplantation seems to offer a very
limited 5-year survival beneﬁt in patients with Child-Pugh
A liver cirrhosis when compared with resection (2.8 [4.4–57]
months) or radio frequency ablation (RFA) ± TACE (5.7 [0.7–11.4]
months) [6].
Moreover, TACE alone is nowadays no longer regarded as the
best therapy for inoperableHCC.Combinationwith radiofrequency
ablation, laser induced thermotherapy, selective internal radio-
therapy (SIRT) or transarterial radioembolisation (TARE) can be
more effective and can control the tumour in up to 70% of cases [7].
We therefore think that the data provided by Otto et al. [1] is
less than convincing in that response to repeated TACE should be
used to discriminate between patients with good/acceptable vs.
impaired/inacceptable prognosis for long-term survival after liver
transplantation. In fact, due to multiple biases there is no evi-
dence provided to support this conclusion of the paper.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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To the Editor:
We appreciate the interest of A. Paul et al. in our recent publica-
reduced recurrence
progression during Ttion ‘‘How to decide about liver transplantation in patients with
hepatocellular carcinoma: Size and number of lesions or response
to TACE?’’ [1]. The point in this publication was to demonstrate
the vagueness of size and number of HCC nodules in initial imag-
ing to predict tumour recurrence when compared to the results of
pretransplant transarterial chemoembolization (TACE). Based on
a cohort of 136 patients uniformly treated by repeated TACE,
the results of the radiological routine assessment before the ﬁrst
TACE and after the last TACE before liver transplantation (LT)
were compared. Carcinomas remaining stable or responding to
TACE during pretreatment had a favourable prognosis. Their
biology, and the pre-treatment used in our cohort was obviously
capable of separating two biologically different groups of
patients. The question remains if response to TACE is really a sur-
rogate of tumour biology or if proof of time is crucial in biological
selection. If time before LT is crucial any other form of pre-treat-
ment would yield similar results. Nothing more – but also noth-
ing less – is claimed in our publication. We cannot see the
‘‘confusion’’ in this statement.
Most other aspects criticised by the authors of the letter go
beyond the scope of our publication. This applies for issues such
as drop-out rate including the rate of patients functionally
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competent physicians in the intervention
n confounders that were not balanced
Unfortunately details of the allocation
are insufﬁcient to determine the levels of
each confounder and whether all patients
atment programs within a similar time-
arge.
ck of process measures performed during
help support claims that the model was
, there were no data conﬁrming that pre-
prescribed were actually taken by patients,
dance at scheduled appointments was
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eteriorating during TACE [2], comparison of LT with liver resec-
on and with forms of HCC treatment such as radiofrequency
blation, TACE using drug eluting beads, 90Yttrium therapy, etc.
e agree that liver resection may offer a similar survival beneﬁt
s LT. That is particularly true for Asian countries, less for the
estern world [3]. This differential indication was, however,
ot the point of our publication. Likewise, the problem if lab-
ELD, matchMELD, regular or rescue allocation impact prognosis
as not intended to be addressed, as it deserves studies using a
uch greater cohort of patients and can, therefore, not be
nswered by a single centre analysis. Even if described in the
ublication we would stress the following aspects mentioned
y the authors of the letter: TNM classiﬁcation usually indicates
TNM and has, therefore, to be deduced from the surgical speci-
en (Table 2, [1]) not being available during the initial assess-
ent. Considerations about the indication for LT in patients
ith T1 or T2 tumours are justiﬁed in scientiﬁc context but must
e questioned in clinical practise due to the impreciseness of
aging (29 of 70 = 41%; [4]). Of course, all patients were
cluded in the overall survival analysis and time from ﬁrst TACE
LT – the only period which is of interest in the study context –
demonstrated in Table 1, [1]. After all, we cannot recognize the
bias’’ challenged in the Letter as the authors ignore the issue of
ur publication.
In one point we agree explicitly with the authors of the sub-
itted letter: A change of the allocation rules based on our pub-
cation would be premature and the ‘‘. . .ﬁnding(s) should be
veriﬁed in a larger pro
tence of the publicatio
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Coordinated care in cirrhosis; the need
randomized controlled tria
o the Editor:
e read with interest the recent study on care coordination for
irrhotic patients by Morando et al., with an accompanying edito-
ial [1,2]. Firstly, we would like to congratulate the Padova group
r focusing their research interest on this important topic and
atient population.
We must, however, correct the statement of the editorialists
at this study represents the ‘‘ﬁrst prospective trial in the
irrhosis population’’ [2]. We highlight the publication of our
wn randomized controlled trial of coordinated cirrhosis care,
hich preceded the publication of the Padova study in the
terature [3].
but instead to more
team or to unknow
between the groups.
procedures provided
stratiﬁcation used for
commenced their tre
frame following disch
There was also a la
the trial, which would
effective. For example
ventative medications
or that patient attenReferencing of our earlier study may have been helpful for the
eadershipbecause, unlike thePadova study, itwas a fully random-
ed controlled trial (RCT) with outcomes that were very different.
e did not detect any improvement in either hospitalization
easures or mortality in the 12 months following an intervention
ith a care co-ordination model.
A major limitation of the Padova study is its lack of a blinded
nd completely randomized group allocation procedure, which
as instead based on retrospective matching of known
onfounders. As a consequence, it remains possible that the
eneﬁcial effects seen were not related to the new care model,
improved. Authors propose increased contacts with specialist
physicians as explanation for improved outcomes in the coordi-
nated care group. However, no analysis was performed to support
the claims for associations between outcomes and greater spe-
cialist visit numbers being associated with reduced risk of
mortality.
In relation tomortality, the authors chose not to discuss the dis-
tribution of events throughout the study. A careful examination of
the Kaplan Meier curves does however reveal some important
details. Firstly, there was an increased risk of death for standard
care patients during the ﬁrst 3 months of the trial relative to
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